KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Gains from Investment Securities: 2013-2025

Historic Gains from Investment Securities for Xenon Pharmaceuticals (XENE) over the last 10 years, with Sep 2025 value amounting to -$89,000.

  • Xenon Pharmaceuticals' Gains from Investment Securities was N/A to -$89,000 in Q3 2025 from the same period last year, while for Mar 2025 it was $12.1 million, marking a year-over-year increase of 13.28%. This contributed to the annual value of $10.7 million for FY2024, which is 20.40% up from last year.
  • According to the latest figures from Q3 2025, Xenon Pharmaceuticals' Gains from Investment Securities is -$89,000, which was down 100.74% from $12.1 million recorded in Q1 2025.
  • In the past 5 years, Xenon Pharmaceuticals' Gains from Investment Securities ranged from a high of $30.4 million in Q4 2024 and a low of -$89,000 during Q3 2025.
  • Over the past 3 years, Xenon Pharmaceuticals' median Gains from Investment Securities value was $9.0 million (recorded in 2023), while the average stood at $11.1 million.
  • Data for Xenon Pharmaceuticals' Gains from Investment Securities shows a peak YoY skyrocketed of 241.96% (in 2024) over the last 5 years.
  • Xenon Pharmaceuticals' Gains from Investment Securities (Quarterly) stood at $5.6 million in 2021, then grew by 26.24% to $7.1 million in 2022, then increased by 24.96% to $8.9 million in 2023, then surged by 241.96% to $30.4 million in 2024, then increased by 13.28% to -$89,000 in 2025.
  • Its Gains from Investment Securities stands at -$89,000 for Q3 2025, versus $12.1 million for Q1 2025 and $30.4 million for Q4 2024.